Sino-Russian Biological Diagnosis Reagents Venture Project Launches in Changzhou High-Tech District

CHANGZHOU, China, March 31 /Xinhua-PRNewswire/ — On March 26, the contract on Sino-Russian diagnosis reagents venture project was formally signed in the Changzhou national high-tech district of Jiangsu Province. Both parties will cooperate to research and develop enzyme-linked immunosorbent assay (ELISA) reagent and biological chips.

The cooperation is based on capital contribution by the Chinese party — Changzhou Fangyuan Pharmaceutical Co. Ltd. and technological patent of Russian party — IMDi Co., Ltd. Changzhou Fangyuan Pharmaceutical Co. Ltd will make use of the existing technology of IMDi to produce enzyme-linked immunosorbent assay (ELISA) reagent and biological chips. According to the contract, the products will be put into production in Changzhou high-tech district and put on to the market this year.

”The disease can be diagnosed quickly through a drop of blood of the patient in some ten minutes or several hours”, according to principal of Fangyuan Pharmaceutical Co. Ltd. Enzyme-linked immunosorbent assay technology can rapidly screens and quantitatively detects the existing of antigen in a sample, clinically. It mainly targets on the regular check and diagnosis of chlamydia, neisseria gonorrhoeae, herpes viruses, AIDS, and virus of hepatitis A, B, and C.

Biological chips technology is a new technology that is rapidly developed in the field of life science in recent years. The technological features of this Sino-Russian cooperation are its strong specificity and high sensitivity. It can carry out early diagnosis of the disease, so as to free the patient from the worries of waiting long period for the inspection results and more helpful to prevent and cure the disease. The pregnancy diagnosis reagent for identifying whether the embryo has suffered from congenital disease has reached international standards, and is mainly used for diagnosis of various inheritable diseases, tumour, viral and other diseases.

It is known that IMDi Co., Ltd has started the scientific development of enzyme-linked immunosorbent assay since 1994. It boasts one of the leading enterprises among enzyme-linked immunosorbent reagents manufacturers. While the research and develop of enzyme-linked immunosorbent reagents in China is just at the beginning, the quality of the reagent product is not stable hence unable to clinically applied in large scale. The implementation of the project will increase the stability of Chinese enzyme-linked immunosorbent reagents, expand it application area, promote the development of Chinese immunity analysis technology and make a domestic breakthrough.

   For more information, please contact:     Wang Zhongliang    Department of Propaganda and United Front Work    Changzhou National High-Tech District, Jiangsu Province    Tel:   +86-519-8512-7305 or +86-130-925-27003    Fax:   +86-519-8511-5905    Email: w_zongliang@sohu.com  

Changzhou National High-Tech District, Jiangsu Province

CONTACT: Wang Zhongliang, Department of Propaganda and United Front Work,Changzhou National High-Tech District, Jiangsu Province, Tel – +86-519-8512-7305, or +86-130-925-27003 , or Fax – +86-519-8511-5905, orw_zongliang@sohu.com

Web site: http://www.czxx.org.cn/